Literature DB >> 26648656

Oral targeted therapy for cancer.

Christine Carrington1.   

Abstract

Oral targeted therapies are increasingly being used to treat cancer. They work by interfering with specific molecules or pathways involved in tumour growth. It is essential that health professionals managing patients taking these drugs have appropriate training and skills. They should be aware of potential adverse effects and drug interactions, and be able to manage toxicities when they occur. Despite the selectivity of these targeted therapies, they still have serious adverse effects including skin reactions, diarrhoea and altered organ function.

Entities:  

Keywords:  adverse effects; drug interactions; targeted cancer therapies; tyrosine kinase inhibitors

Year:  2015        PMID: 26648656      PMCID: PMC4657306          DOI: 10.18773/austprescr.2015.060

Source DB:  PubMed          Journal:  Aust Prescr        ISSN: 0312-8008


  24 in total

1.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

Authors:  Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean Jacques Grob; Vanna Chiarion Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymyr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Michelle Casey; Daniele Ouellet; Anne-Marie Martin; Ngocdiep Le; Kiran Patel; Keith Flaherty
Journal:  N Engl J Med       Date:  2014-09-29       Impact factor: 91.245

Review 2.  Novel agents and approaches for advanced renal cell carcinoma.

Authors:  Robert Figlin; Cora Sternberg; Christopher G Wood
Journal:  J Urol       Date:  2012-07-19       Impact factor: 7.450

3.  Current treatment for multiple myeloma.

Authors:  David Avigan; Jacalyn Rosenblatt
Journal:  N Engl J Med       Date:  2014-09-04       Impact factor: 91.245

4.  Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye.

Authors:  Guo Yu; Qing-Shan Zheng; Da-Xin Wang; Hong-Hao Zhou; Guo-Fu Li
Journal:  Lancet Oncol       Date:  2014-10       Impact factor: 41.316

Review 5.  Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.

Authors:  Jenny C Hu; Parrish Sadeghi; Lauren C Pinter-Brown; Sharona Yashar; Melvin W Chiu
Journal:  J Am Acad Dermatol       Date:  2006-12-01       Impact factor: 11.527

Review 6.  Guidance on the management of diarrhoea during cancer chemotherapy.

Authors:  Jervoise Andreyev; Paul Ross; Clare Donnellan; Elaine Lennan; Pauline Leonard; Caroline Waters; Linda Wedlake; John Bridgewater; Rob Glynne-Jones; William Allum; Ian Chau; Richard Wilson; David Ferry
Journal:  Lancet Oncol       Date:  2014-09       Impact factor: 41.316

7.  Pazopanib: in advanced soft tissue sarcoma.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

Review 8.  Medical management of malignant melanoma.

Authors:  Victoria Atkinson
Journal:  Aust Prescr       Date:  2015-03-11

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

Review 10.  Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

Authors:  Mario E Lacouture; Milan J Anadkat; René-Jean Bensadoun; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Barbara A Murphy
Journal:  Support Care Cancer       Date:  2011-06-01       Impact factor: 3.603

View more
  4 in total

1.  Developing an Improved Statistical Approach for Survival Estimation in Bone Metastases Management: The Bone Metastases Ensemble Trees for Survival (BMETS) Model.

Authors:  Sara R Alcorn; Jacob Fiksel; Jean L Wright; Christen R Elledge; Thomas J Smith; Powell Perng; Sarah Saleemi; Todd R McNutt; Theodore L DeWeese; Scott Zeger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-05-22       Impact factor: 7.038

Review 2.  Reviewing the role of healthy volunteer studies in drug development.

Authors:  Joyson J Karakunnel; Nam Bui; Latha Palaniappan; Keith T Schmidt; Kenneth W Mahaffey; Briggs Morrison; William D Figg; Shivaani Kummar
Journal:  J Transl Med       Date:  2018-12-04       Impact factor: 5.531

Review 3.  Chronic leukaemias in the community.

Authors:  Eric Wenlong Li; David Yeung; Stephen Fuller
Journal:  Aust Prescr       Date:  2020-08-03

Review 4.  Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma.

Authors:  Vida Mashayekhi; Orsola Mocellin; Marcel H A M Fens; Gerard C Krijger; Lodewijk A A Brosens; Sabrina Oliveira
Journal:  Theranostics       Date:  2021-08-25       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.